offer
all report title image
  • Published On : Jun 2022
  • Code : CMI5038
  • Industry : Pharmaceutical
  • Pages : 149
  • Formats :

The increasing adoption of strategies such as acquisitions & agreement by key players is expected to drive the market growth over the forecast period. For instance, in September 2020, Hester Biosciences Limited signed an agreement with IVRI (Indian Veterinary Research Institute), an institute under the Indian Council of Agricultural Research (ICAR), to acquire Brucella vaccine technology for developing the Brucella Abortus S19 Delta Pevaccine from IVRI Hester, which manufactures the conventional Brucella Abortus S19 vaccine and supplies it to all the states in India. The S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced immunogenicity and safety, assuring lifelong immunity with a single shot in calf-hood. 

The global Brucellosis Vaccines Market is estimated to be valued at US$ 224.64 million in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030)

Figure 1. Global Brucellosis Vaccines Market Share (%) in Terms of Value, By Region, 2022

Brucellosis Vaccines  | Coherent Market Insights

Increasing investments by key players in market for expansion of brucellosis manufacturing facilities is expected to drive market growth over the forecast period.

For instance, in August 2019, Biovet Private Ltd, an animal health vaccine producing company located in Karnataka, India, announced that it will invest US$ 26,212,600 (Rs 200 crore) for expanding its foot & mouth and brucellosis vaccine manufacturing facilities in Malur, Karnataka, India. This is expected to drive market growth over the forecast period.

CMI table icon

Brucellosis Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 224.64 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.7% 2030 Value Projection: US$ 324.83 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: RB51 Vaccine, S19 Vaccine, B19 Vaccine, Others (45/20 vaccine, SR82 vaccine, etc.)
  • By Application: Cattle, Sheep, Goat, Others (swine, horses, etc.)
Companies covered:

Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.

Growth Drivers:
  • Increasing prevalence of brucellosis
  • Increasing government initiatives
Restraints & Challenges:
  • Drawbacks associated with brucellosis vaccines

Figure 2. Global Brucellosis Vaccines Market Share (%), by Type, 2022

Brucellosis Vaccines  | Coherent Market Insights

Global Brucellosis Vaccines Market: Restraint

Drawbacks associated with use of brucellosis vaccines is expected to act as a restraint for the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the Journal of Veterinary Science, an international, peer-reviewed, open-access journal of veterinary medicine, in August 2017, currently available brucellosis vaccines exhibit one or more major drawbacks such as residual virulence and serodiagnostic interference. Moreover, according to an article published by the journal Veterinary Research, an open access journal that publishes high quality novel research and review articles, in July 2015, although the available vaccines are effective in controlling brucellosis, they have numerous drawbacks such as interference with diagnostic tests, pathogenicity for humans, and potential to cause abortion in pregnant animals, among others.

Key Players

Major players operating in the global brucellosis vaccines market include Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.

Brucellosis is an infectious disease caused by bacteria. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs, among others. These disease can also occur in humans when they are in contact with infected animals or animal products contaminated with bacteria.

Moreover, RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.) are the type of vaccine used for the brucellosis in animals.

Furthermore, increasing launches of brucellosis vaccination programmes is expected to drive the market growth over the forecast period.

In August 2021, brucella vaccination program was launched at Thoubal, Manipur, India for the control and eradication of brucellosis in female calves of 4-8 months age group.

Market Dynamics

Increasing prevalence of brucellosis is expected to drive the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, brucellosis is the world’s most widespread zoonotic disease, a type of disease that passes from an animal to a human. The source stated that there are a reported 500,000 cases of human brucellosis each year, globally. However, true incidence is estimated to be 5,000,000 to 12,500,000 cases each year, globally.

According to the same source, brucellosis is recognized as the world’s most common laboratory-acquired infection.

Key features of the study:

  • This report provides an in-depth analysis of the global brucellosis vaccines market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global brucellosis vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health and VETAL Animal Health Products Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global brucellosis vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brucellosis vaccines market

Detailed Segmentation:

  • Global Brucellosis Vaccines Market, By Type:
    • RB51 Vaccine
    • S19 Vaccine
    • B19 Vaccine
    • Others (45/20 vaccine, SR82 vaccine, etc.)
  • Global Brucellosis Vaccines Market, By Application:
    • Cattle
    • Sheep
    • Goat
    • Others (swine, horses, etc.)
  • Global Brucellosis Vaccines Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Competitive Snapshot
      • Merck & Co., Inc.*
        • Company Overview
        • Application Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CZ Vaccines
      • Colorado Serum Company
      • Indian Immunologicals Ltd.
      • Hester Biosciences Limited
      • Veterinary Technologies Corporation
      • Jordan Bio-industries Center
      • Laboratorios Tornel
      • Fivet Animal Health
      • VETAL Animal Health Products Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global brucellosis vaccines market size is estimated to be valued at US$ 224.64 Mn in 2022 and expected to exhibit a CAGR of 4.7% between 2022 and 2030.
Increasing prevalence of brucellosis and increasing government initiatives are expected to drive market growth over the forecast period.
RB51 Vaccine is leading type segment in the market.
North America holds the largest market share in the market.
Major factors hampering the market growth include drawbacks associated with brucellosis vaccines.
Major players operating in the market include Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo